InCephalo Therapeutics

Executive Summary

InCephalo Therapeutics is a Swiss biotechnology company pioneering a novel approach to treating brain diseases, with an initial focus on glioblastoma (GBM), an aggressive and incurable brain cancer. The company’s proprietary C-Lock™ technology enables the delivery of potent immune-activating biologics, such as cytokines, directly to brain tumors while preventing systemic exposure and associated toxicities. This compartment-locked strategy aims to overcome the blood-brain barrier and the immunosuppressive tumor microenvironment, which have historically limited the efficacy of immunotherapies in GBM. Founded in 2018 and headquartered in Basel, Switzerland, InCephalo is advancing its lead candidate, a C-Lock-enabled cytokine, through Phase 1/2 clinical trials. The company represents a compelling approach to addressing the high unmet need in GBM, where current standard-of-care offers limited survival benefit. Its platform technology has the potential to be applied to other central nervous system malignancies and inflammatory disorders, broadening its therapeutic scope.

Upcoming Catalysts (preview)

• Q1 2027Interim Phase 1/2 safety and efficacy data readout50% success
• Q4 2026Initiation of Phase 2 expansion cohort in recurrent GBM70% success
• Q2 2027Potential partnership or licensing deal for C-Lock platform40% success